natgillin/translations-raw huggingface dataset:
In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.
Selektivnost sildenafila je več kot 4000-krat večja za PDE5 kot za PDE3 - za cAMP specifično izoobliko fosfodiesteraze, ki sodeluje pri nadzoru krčljivosti srca.
*Reported during post-marketing surveillance only **Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia ***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased
*O tem so poročali v obdobju trženja **Motnje zaznavanja barv: kloropsija, kromatopsija, cianopsija, eritropsija in ksantopsija ***Motnje solzenja: suhe oči, motnje solzenja in povečanjo solzenje
Vizarsin contains sorbitol (E420).
Zdravilo Vizarsin vsebuje sorbitol (E420).
The dosing recommendations described in ‘Use in adults' apply to patients with mild to moderate renal impairment (creatinine clearance = 30-80 ml/min).
Priporočila za odmerjanje (glejte odstavek Uporaba pri odraslih) veljajo tudi za bolnike z blago do zmerno ledvično okvaro (očistek kreatinina 30 do 80 ml/min).
- The other ingredients are hydroxypropylcellulose (E463), mannitol (E421), aspartame (E951),
- Druge sestavine zdravila so hidroksipropilceluloza (E463), manitol (E421), aspartam (E951),
Vizarsin is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Zdravilo Vizarsin je kontraindicirano pri bolnikih, ki so izgubili vid na enem očesu zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), tudi če ta dogodek ni bil povezan s predhodnim jemanjem zaviralcev PDE5 (glejte poglavje 4.4).
These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section 5.1).
Dodatno znižanje krvnega tlaka je bilo podobno kot pri dajanju samega sildenafila zdravim prostovoljcem (glejte poglavje 5.1).
Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
Med bolnike s povečano občutljivostjo za vazodilatatorje spadajo bolniki z obstrukcijo iztoka iz levega prekata (npr. z aortno stenozo, hipertrofično obstruktivno kardiomiopatijo) ali z redkim sindromom multiple sistemske atrofije, ki se kaže kot huda okvara avtonomnega uravnavanja krvnega tlaka.
The recommended dose is 50 mg taken as needed approximately one hour before sexual activity.
Vzeti ga je treba po potrebi, približno eno uro pred spolno dejavnostjo.
Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg).
Sildenafil (50 mg) ni dodatno podaljšal časa krvavitve, podaljšanega že zaradi acetilsalicilne kisline (150 mg).
In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n=9), sildenafil (single dose, 100 mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).
V majhni s placebom nadzorovani raziskavi pri bolnikih s potrjeno zgodnjo starostno degeneracijo makule (n = 9) sildenafil v enkratnem 100-mg odmerku ni pomembno vplival na preiskave vida (ostrina vida, Amslerjeva mrežica, ločevanje barv na simuliranem semaforju, Humphreyev perimeter in fotostres).
Agents for the treatment of erectile dysfunction, including sildenafil, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
Zdravila za zdravljenje erektilne disfunkcije, vključno s sildenafilom, je treba previdno uporabljati pri bolnikih z anatomskimi deformacijami penisa (npr. z angulacijo, kavernozno fibrozo ali Peyroniejevo boleznijo) in pri bolnikih z nekaterimi boleznimi, ki povzročajo nagnjenost k priapizmu (npr. s srpastocelično anemijo, multiplim mielomom ali levkemijo).
- If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy (NAION).
- Če ste kadarkoli izgubili vid zaradi nearteritične anteriorne ishemične optične nevropatije (NAION).
Vizarsin tablets may interfere with some medicines, especially those used to treat chest pain.
Zdravilo Vizarsin lahko vpliva na delovanje nekaterih zdravil, zlasti zdravil proti angini pektoris.
You may find that Vizarsin takes longer to work if you take it with a heavy meal.
Morda boste ugotovili, da zdravilo začne delovati kasneje, če ga zaužijete s težjim obrokom.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (>70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
V raziskavi hemodinamičnih učinkov enkratnega peroralnega 100-mg odmerka sildenafila pri 14 bolnikih s hudo boleznijo koronarnih arterij (> 70-% stenoza vsaj ene koronarne arterije) se je srednji sistolični tlak v mirovanju v primerjavi z izhodiščem znižal za 7 %, povprečni diastolični tlak v mirovanju pa za 6 %.
The orodispersible tablets may be used as an alternative to Vizarsin film-coated tablets for patients who have difficulty to swallow film-coated tablets.
Orodisperzibilne tablete so namenjene bolnikom, ki imajo težave s požiranjem filmsko obloženih tablet Vizarsin.
Vizarsin contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Zdravilo Vizarsin vsebuje zdravilno učinkovino sildenafil, ki sodi med zdravila, ki jih imenujemo zaviralci fosfodiesteraze tipa 5 (PDE5).
The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied.
Varnost in učinkovitost kombinacije sildenafila z drugimi zaviralci PDE5, drugimi zdravili proti pljučni arterijski hipertenziji (PAH), ki vsebujejo sildenafil, ali z drugimi zdravili za zdravljenje erektilne disfunkcije nista raziskani, zato uporaba takih kombinacij ni priporočljiva.
Although no increased incidence of adverse events was observed in these patients, when sildenafil is administered concomitantly with CYP3A4 inhibitors, a starting dose of 25 mg should be considered.
Čeprav pri teh bolnikih niso ugotovili večje pogostosti neželenih učinkov, je pri sočasnem jemanju z zaviralci CYP3A4 priporočljiv začetni odmerek, tj. 25 mg.
Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years).
Pri zdravih starejših prostovoljcih (starih 65 let ali več) je bil očistek sildenafila manjši, zato je bila koncentracija sildenafila in aktivnega N-desmetilnega presnovka v plazmi za približno 90 % večja kot pri mlajših zdravih prostovoljcih (od 18 do 45 let).
If Vizarsin is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2).
Če se zdravilo Vizarsin zaužije s hrano, lahko začne delovati pozneje, kot če je zaužito na prazen želodec (glejte poglavje 5.2).
Initiation of sildenafil at a dose of 25 mg should be considered (see section 4.2).
Razmisliti je treba o uvedbi sildenafila v odmerku po 25 mg (glejte poglavje 4.2).
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
Posebne raziskave interakcij niso bile narejene za vsa zdravila, populacijske farmakokinetične analize niso pokazale vpliva na farmakokinetiko sildenafila pri sočasnem zdravljenju z zdravili iz skupine zaviralcev CYP2C9 (npr. tolbutamid, varfarin, fenitoin) ali zaviralcev CYP2D6 (npr. selektivni zaviralci prevzema serotonina, triciklični antidepresivi), tiazidi in sorodnimi diuretiki, diuretiki Henlejeve zanke in diuretiki, ki varčujejo s kalijem, zaviralci ACE, zaviralci kalcijevih kanalčkov, antagonisti adrenergičnih receptorjev beta ali induktorji presnove s CYP450 (npr. rifampicin ali barbiturati).
After oral dosing of sildenafil AUC and Cmax increase in proportion with dose over the recommended dose range (25-100 mg).
Po peroralni uporabi sildenafila se AUC in Cmax v priporočenem razponu odmerkov (od 25 do 100 mg) povečujeta sorazmerno z odmerkom.
Contains aspartame (E951) and peppermint oil (sorbitol (E420)).
Vsebuje aspartam (E951) in eterično olje poprove mete (sorbitol (E420)).
The mean maximum decreases in supine systolic blood pressure following 100 mg oral dosing of sildenafil was 8.4 mmHg.
Srednje največje znižanje sistoličnega krvnega tlaka, merjenega leže, je bilo po 100-mg peroralnem odmerku sildenafila 8,4 mmHg.
Your doctor should carefully check whether your heart can take the additional strain of having sex.
- če imate težave s srcem; zdravnik mora v tem primeru natančno preveriti, ali vaše srce lahko prenese dodatni napor, ki je povezan s spolnimi odnosi;
Blister (PVC-foil/Alu-foil): 1 film-coated tablet, in a carton.
Pretisni omot (PVC-folija/Al-folija): 1 filmsko obložena tableta, v škatli.
Talk to your doctor or pharmacist before taking Vizarsin: - If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).
Pred začetkom jemanja zdravila Vizarsin se posvetujte z zdravnikom ali farmacevtom: Povejte zdravniku: - če imate srpastocelično anemijo (nepravilnost rdečih krvnih celic), levkemijo (rak krvnih celic),
Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
Cimetidin (800 mg), zaviralec citokroma P450 in nespecifični zaviralec CYP3A4, je ob sočasni uporabi s sildenafilom (50 mg) pri zdravih prostovoljcih povzročil 56-% povečanje koncentracije sildenafila v plazmi.
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment.
Pri prostovoljcih z blago do zmerno cirozo jeter (Child-Pugh A in B) je bil očistek sildenafila zmanjšan, kar je povzročilo povečanje AUC (84 %) in Cmax (47 %) v primerjavi s prostovoljci primerljive starosti brez jetrne okvare.
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 > 150 μM).
Sildenafil je šibek zaviralec izoencimov 1A2, 2C9, 2C19, 2D6, 2E1 in 3A4 citokroma P450 (IC50 > 150 μM).
Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.
Posledica je povečanje koncentracije cikličnega gvanozinmonofosfata (cGMP), kar povzroči sprostitev gladkih mišic v corpusu cavernosumu in omogoči dotok krvi.
Vizarsin contains aspartame (E951) and sorbitol (E420) Aspartame is a source of phenylalanine which may be harmful for people with a disorder called phenylketonuria.
Zdravilo Vizarsin vsebuje aspartam (E951) in sorbitol (E420) Aspartam je vir fenilalanina, ki lahko škoduje ljudem s fenilketonurijo.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000).
Pogostost je opredeljena na naslednji način: zelo pogosti (> 1/10), pogosti (> 1/100, < 1/10), občasni (> 1/1.000, < 1/100) in redki (> 1/10.000, < 1/1.000).
Given sildenafil peak plasma concentrations of approximately 1 M after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes.
Ker je največja koncentracija sildenafila v plazmi po priporočenih odmerkih približno 1 µM, ni verjetno, da bi sildenafil spremenil očistek substratov teh izoencimov.
Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see section 4.3).
V skladu z znanimi učinki sildenafila na pot dušikovega oksida/cGMP (glejte poglavje 5.1) je dokazano, da sildenafil stopnjuje hipotenzivne učinke nitratov, zato je njegova hkratna uporaba z donorji dušikovega oksida ali nitrati v kakršnikoli obliki kontraindicirana (glejte poglavje 4.3).
Given sildenafil peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes.
Ker je največja koncentracija sildenafila v plazmi po priporočenih odmerkih približno 1 μM, ni verjetno, da bi sildenafil spremenil očistek substratov teh izoencimov.
Film coating: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518).
Filmska obloga: laktoza monohidrat, hipromeloza (E464), titanov dioksid (E171), triacetin (E1518).
For 4 tablets per blister:
za 4 tablete na pretisni omot:
Sildenafil has a peripheral site of action on erections.
Sildenafil periferno vpliva na erekcijo.
This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% that of the parent drug.
Selektivnost tega presnovka za fosfodiesteraze je podobna sildenafilovi, njegov vpliv na PDE5 pa in vitro znaša približno 50 % vpliva prvotnega zdravila.
For 1 tablet per blister:
za 1 tableto na pretisni omot:
It can be taken with or without liquid.
Bolnik jo lahko pogoltne s tekočino ali brez nje.
In volunteers with severe renal impairment (creatinine clearance <30 ml/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88% respectively compared to age-matched volunteers with no renal impairment.
Pri prostovoljcih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) se je očistek sildenafila zmanjšal, to pa je povzročilo povprečno povečanje AUC za 100 % in Cmax za 88 % v primerjavi s prostovoljci primerljive starosti brez ledvične okvare.
CARTON for monolingual and bilingual packaging
ŠKATLA za enojezično in dvojezično pakiranje
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Triacetin (E1518)
Filmska obloga: laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) triacetin (E1518)
- An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.
- Alergijske reakcije-to se zgodi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) Simptomi vključujejo nenadno zadihanost, težave pri dihanju ali omotico, oteklino očesnih vek, obraza, ustnic ali grla.
This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity.
Gre za motnjo, pri kateri moškemu spolni ud ne otrdi ali ne ostane dovolj otrdel, da bi bila mogoča spolna dejavnost.
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%).
V vseh preizkušanjih skupaj so bili deleži bolnikov, ki so po sildenafilu navajali izboljšanje, naslednji: 84 % bolnikov s psihogeno erektilno disfunkcijo, 77 % z mešano erektilno disfunkcijo, 68 % z organsko erektilno disfunkcijo, 67 % starostnikov, 59 % s sladkorno boleznijo, 69 % z ishemično boleznijo srca, 68 % z zvišanim krvnim tlakom, 61 % z transuretralno resekcijo prostate, 43 % z radikalno prostatektomijo, 83 % s poškodbo hrbtenjače in 75 % z depresijo.
BLISTER for monolingual and bilingual packaging
PRETISNI OMOT za enojezično in dvojezično pakiranje
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5).
Previdnost je potrebna med uporabo sildenafila pri bolnikih, ki jemljejo antagonisti adrenergičnih receptorjev alfa, saj sočasno jemanje pri maloštevilnih občutljivih posameznikih lahko povzroči simptomatsko hipotenzijo (glejte poglavje 4.5).
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased.
V raziskavah, v katerih so pri zdravih prostovoljcih ugotavljali učinek enega, do 800-mg odmerka, so bili neželeni učinki podobni kot pri manjših odmerkih, le pogostejši in izrazitejši.
To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Vizarsin.
Da bi zmanjšali verjetnost za pojav teh simptomov, morate pred začetkom jemanja zdravila Vizarsin redno jemati dnevni odmerek antagonista adrenergičnih receptorjev alfa.
Each orodispersible tablet contains 0.375 mg aspartame (E951) and 0.00875 mg sorbitol (E420).
Ena orodispezibilna tableta vsebuje 0,375 mg aspartama (E951) in 0,00875 mg sorbitola (E420).
This is most likely to occur within 4 hours post sildenafil dosing.
Verjetnost, da se to zgodi, je največja v štirih urah po odmerku sildenafila.
Vizarsin with food, drink and alcohol
Zdravilo Vizarsin skupaj s hrano, pijačo in alkoholom Zdravilo Vizarsin lahko zaužijete s hrano ali brez nje.
1 film-coated tablet 4 x 1 film-coated tablet 8 x 1 film-coated tablet 12 x 1 film-coated tablet
1 filmsko obložena tableta 4 x 1 filmsko obložena tableta 8 x 1 filmsko obložena tableta 12 x 1 filmsko obložena tableta
Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated.
Znano je, da sildenafil učinkuje na pot dušikov oksid/ciklični gvanozinmonofosfat (cGMP) (glejte poglavje 5.1) in tako okrepi hipotenzivno delovanje nitratov, zato je sočasno jemanje z donorji dušikovega oksida (npr. z amilnitritom) ali nitrati v kakršnikoli obliki kontraindicirano.
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).
Ob uporabi enega 100-mg odmerka sildenafila hkrati z eritromicinom, zmernim zaviralcem CYP3A4, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan pet dni) prišlo do 182-% povečanja sistemske izpostavljenosti (AUC) sildenafilu.
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and vision blurred.
Pri bolnikih, zdravljenih s sildenafilom, so v kliničnih preizkušanjih najpogosteje poročali o naslednjih neželenih učinkih: glavobol, zardevanje, dispepsija, zamašenost nosu, omotica, navzea, vročinski oblivi, motnje vida, cianopsija in zamegljen vid.
In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.
V namenski raziskavi interakcij, v kateri so bolniki z zvišanim krvnim tlakom sočasno jemali sildenafil (100 mg) in amlodipin, se je njihov sistolični krvni tlak, merjen leže, dodatno znižal za 8 mmHg, diastolični krvni tlak pa za 7 mmHg.
You should not use Vizarsin with any other oral or local treatments for erectile dysfunction.
Hkrati z zdravilom Vizarsin za zdravljenje erektilne disfunkcije ne smete uporabljati nobenega drugega zdravila za peroralno ali lokalno uporabo.
Blister (peel open blister, Oriented Polyamide/Aluminium/PVC//PET/Aluminium): 1 orodispersible tablet, in a carton.
Pretisni omot (folija, ki se odlepi, usmerjen poliamid/aluminij/PVC//PET/aluminij): 1 orodisperzibilna tableta, v škatli.
BLISTER for trilingual packaging
ŠKATLA za trijezično pakiranje
Each orodispersible tablet contains 25 mg, 50 mg or 100 mg sildenafil.
Ena orodispezibilna tableta vsebuje 25 mg, 50 mg ali 100 mg sildenafila.
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC.
Sočasno jemanje zaviralca proteaz HIV ritonavirja, ki je zelo močan zaviralec P450, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan) in sildenafila (enkratni odmerek 100 mg) povzročilo 300 % (4-kratno) povečanje Cmax sildenafila in 1.000 % (11-kratno) povečanje AUC sildenafila v plazmi.
/c '
I <K'.
Co-administration of sildenafil with ritonavir is not advised (see section 4.5).
Sočasno jemanje sildenafila in ritonavirja ni priporočljivo (glejte poglavje 4.5).
- If you are using any of the medicines known as nitric oxide donors such as amyl nitrite
- Če jemljete zdravila, ki so znana kot dajalci dušikovega oksida, kot je na primer amilnitrit ("poppers" - nelegalno spolno poživilo).
Vizarsin 50 mg orodispersible tablets Each orodispersible tablet contains 0.75 mg aspartame (E951) and 0.0175 mg sorbitol (E420).
Vizarsin 50 mg orodisperzibilne tablete Ena orodispezibilna tableta vsebuje 0,75 mg aspartama (E951) in 0,0175 mg sorbitola (E420).
Concomitant use with alpha-blockers
Sočasna uporaba z antagonisti adrenergičnih receptorjev alfa
Vizarsin 100 mg orodispersible tablets Each orodispersible tablet contains 1.5 mg aspartame (E951) and 0.035 mg sorbitol (E420).
Vizarsin 100 mg orodisperzibilne tablete Ena orodispezibilna tableta vsebuje 1,5 mg aspartama (E951) in 0,035 mg sorbitola (E420).
Microcrystalline cellulose (E460) Anhydrous calcium hydrogen phosphate Croscarmellose sodium Hypromellose (E464) Magnesium stearate (E572)
Jedro tablete: mikrokristalna celuloza (E460) kalcijev hidrogenfosfat, brezvodni premreženi natrijev karmelozat hipromeloza (E464) magnezijev stearat (E572)
The mean AUC and Cmax of the N-desmethyl metabolite increased up to 126% and up to 73% respectively, compared to age-matched volunteers with no renal impairment.
Srednja AUC N-desmetilnega presnovka se je povečala za do 126 %, srednji Cmax pa za do 73 % v primerjavi s prostovoljci primerljive starosti brez ledvične okvare.
Vizarsin 25 mg film-coated tablets Each film-coated tablet contains 1.9 mg lactose (as monohydrate).
Vizarsin 25 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 1,9 mg laktoze (v obliki monohidrata).
Vizarsin 50 mg film-coated tablets Each film-coated tablet contains 3.8 mg lactose (as monohydrate).
Vizarsin 50 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 3,8 mg laktoze (v obliki monohidrata).